Cellectar Biosciences
CLRB
20 hedge funds and large institutions have $4.28M invested in Cellectar Biosciences in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 6 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
11% more capital invested
Capital invested by funds: $3.85M → $4.28M (+$432K)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
13% less funds holding
Funds holding: 23 → 20 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$1.55M |
| 2 |
FIA
FNY Investment Advisers
New York
|
+$98.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$71.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$33.2K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$12.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$460K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$294K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$179K |
| 4 |
QP
Quilter Plc
London,
United Kingdom
|
-$104K |
| 5 |
Two Sigma Advisers
New York
|
-$71K |
CLRB Hedge Fund Activity: Q3 2020 in Review
20 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2020, worth a combined $4.28M — up 11% from $3.85M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CLRB and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Sio Capital Management, adding an estimated $1.55M. The largest seller was Renaissance Technologies, cutting an estimated $460K.
- 20 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2020, down from 23 in Q2 2020.
- Funds reported $4.28M of Cellectar Biosciences stock for Q3 2020, up 11% quarter-over-quarter.
- 3 funds opened new Cellectar Biosciences positions in Q3 2020 and 6 closed out, a net change of -3 holders.
- The largest Cellectar Biosciences buyer in Q3 2020 was Sio Capital Management, an estimated $1.55M added.
- The largest Cellectar Biosciences seller in Q3 2020 was Renaissance Technologies, an estimated $460K sold.
Based on aggregated 13F filings for Q3 2020.